Gavreto (pralsetinib) vs Krazati (adagrasib)
Gavreto (pralsetinib) vs Krazati (adagrasib)
Gavreto (pralsetinib) and Krazati (adagrasib) are both targeted therapies used to treat certain types of non-small cell lung cancer (NSCLC) with specific genetic mutations. Gavreto is designed to inhibit RET fusion-positive NSCLC, and it is approved for patients with metastatic RET fusion-positive NSCLC. Krazati, on the other hand, targets KRAS G12C-mutated NSCLC and is indicated for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. The choice between these two medications would be guided by the specific genetic mutation present in the cancer, as determined by molecular testing.
Difference between Gavreto and Krazati
| Metric | Gavreto (pralsetinib) | Krazati (adagrasib) |
|---|---|---|
| Generic name | Pralsetinib | Adagrasib |
| Indications | For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) | For the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, after at least one prior systemic therapy |
| Mechanism of action | RET kinase inhibitor | KRASG12C inhibitor |
| Brand names | Gavreto | Krazati |
| Administrative route | Oral | Oral |
| Side effects | Includes hypertension, fatigue, constipation, musculoskeletal pain, and diarrhea | Includes diarrhea, nausea, fatigue, musculoskeletal pain, and liver enzyme elevation |
| Contraindications | Hypersensitivity to pralsetinib or any of its components | Hypersensitivity to adagrasib or any of its components |
| Drug class | Tyrosine kinase inhibitor | Small molecule kinase inhibitor |
| Manufacturer | Genentech, Inc. | Mirati Therapeutics, Inc. |
Efficacy
Gavreto (pralsetinib) Efficacy in Lung Cancer
Gavreto (pralsetinib) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with rearrangements in the RET gene (RET fusion-positive). The efficacy of Gavreto was demonstrated in a clinical trial that included patients with RET fusion-positive NSCLC who were previously untreated or had received prior treatment. The trial showed a significant response rate, with a majority of patients experiencing tumor shrinkage. This response was also found to be durable, with many patients maintaining their response for six months or longer.
In patients who were treatment-naive, the response to Gavreto was particularly notable. The objective response rate (ORR) was high, indicating that the drug effectively inhibited tumor growth in a substantial proportion of patients. Additionally, Gavreto has shown a favorable safety profile, making it a viable option for patients with this specific genetic alteration in their lung cancer.
Krazati (adagrasib) Efficacy in Lung Cancer
Krazati (adagrasib) is another novel medication that targets a specific mutation in lung cancer. It is designed to inhibit the KRAS G12C mutation, which is a driver of cancer growth in a subset of patients with NSCLC. While Krazati is still under clinical investigation, early trial results have shown promise in patients with advanced NSCLC harboring the KRAS G12C mutation. The drug has demonstrated an ability to achieve tumor shrinkage in a significant number of patients, with some experiencing a partial or complete response to the treatment.
The clinical trials assessing the efficacy of Krazati in lung cancer are ongoing, and more data is expected to further define its role in the treatment landscape. However, the preliminary results suggest that Krazati could offer a new therapeutic option for patients with NSCLC who have the KRAS G12C mutation, a group for whom targeted therapies were previously unavailable. As research continues, Krazati may become an important addition to the arsenal of treatments for lung cancer, particularly for those with this specific genetic profile.
Regulatory Agency Approvals
Gavreto
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Krazati
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Gavreto or Krazati today
If Gavreto or Krazati are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us